Brief: Black Diamond Therapeutics Announces FDA Allowance Of IND Application For BDTX-1535
Jan 11 (Reuters) - Black Diamond Therapeutics Inc BDTX.O :
* BLACK DIAMOND THERAPEUTICS ANNOUNCES FDA ALLOWANCE OF IND APPLICATION FOR
BDTX-1535, A MASTERKEY INHIBITOR OF EGFR FOR THE TREATMENT OF GLIOBASTOMA AND
NON-SMALL CELL LUNG CANCER
* BLACK DIAMOND THERAPEUTICS INC - EXPECTS TO INITIATE PHASE 1 STUDY OF
BDTX-1535
IN Q1 OF 2022
Source text for Eikon: ID:nGNX353sM6
Further company coverage: BDTX.O
Recent news on Black Diamond Therapeutics
See all newsBlack Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Black Diamond Therapeutics Q2 net loss narrows year over year
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox